Fintel reports that on December 9, 2025, Oppenheimer maintained coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a Outperform recommendation.
Analyst Price Forecast Suggests 22.81% Downside
As of December 6, 2025, the average one-year price target for Terns Pharmaceuticals is $31.05/share. The forecasts range from a low of $17.17 to a high of $37.80. The average price target represents a decrease of 22.81% from its latest reported closing price of $40.23 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Terns Pharmaceuticals is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -1.95.
What is the Fund Sentiment?
There are 272 funds or institutions reporting positions in Terns Pharmaceuticals. This is an decrease of 10 owner(s) or 3.55% in the last quarter. Average portfolio weight of all funds dedicated to TERN is 0.15%, an increase of 50.83%. Total shares owned by institutions increased in the last three months by 6.47% to 95,206K shares. 
The put/call ratio of TERN is 0.28, indicating a bullish outlook.
What are Other Shareholders Doing?
Soleus Capital Management holds 8,127K shares representing 9.02% ownership of the company. In its prior filing, the firm reported owning 8,167K shares , representing a decrease of 0.49%. The firm increased its portfolio allocation in TERN by 52.31% over the last quarter.
Orbimed Advisors holds 7,563K shares representing 8.40% ownership of the company. No change in the last quarter.
Deep Track Capital holds 7,495K shares representing 8.32% ownership of the company. No change in the last quarter.
Vivo Capital holds 6,896K shares representing 7.66% ownership of the company. No change in the last quarter.
Commodore Capital holds 5,700K shares representing 6.33% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
